RT Journal Article
T1 Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on Ustekinumab.
A1 Chaparro, Maria
A1 Baston-Rey, Iria
A1 Fernandez-Salgado, Estela
A1 Gonzalez-Garcia, Javier
A1 Ramos, Laura
A1 Diz-Lois Palomares, Maria Teresa
A1 Argüelles-Arias, Federico
A1 Iglesias-Flores, Eva
A1 Cabello, Mercedes
A1 Rubio-Iturria, Saioa
A1 Nuñez-Ortiz, Andrea
A1 Charro, Mara
A1 Ginard, Daniel
A1 Dueñas-Sadornil, Carmen
A1 Merino-Ochoa, Olga
A1 Busquets, David
A1 Iyo, Eduardo
A1 Gutierrez-Casbas, Ana
A1 Ramirez-de-la-Piscina, Patricia
A1 Bosca-Watts, Marta Maia
A1 Arroyo, Maite
A1 Garcia, Maria Jose
A1 Hinojosa, Esther
A1 Gordillo, Jordi
A1 Martinez-Montiel, Pilar
A1 Velayos-Jimenez, Benito
A1 Quilez-Ivorra, Cristina
A1 Vazquez-Moron, Juan Maria
A1 Huguet, Jose Maria
A1 Gonzalez-Lama, Yago
A1 Muñagorri-Santos, Ana Isabel
A1 Amo, Victor Manuel
A1 Martin-Arranz, Maria Dolores
A1 Bermejo, Fernando
A1 Martinez-Cadilla, Jesus
A1 Rubin-de-Celix, Cristina
A1 Fradejas-Salazar, Paola
A1 Lopez-San-Roman, Antonio
A1 Jimenez, Nuria
A1 Garcia-Lopez, Santiago
A1 Figuerola, Anna
A1 Jimenez, Itxaso
A1 Martinez-Cerezo, Francisco Jose
A1 Taxonera, Carlos
A1 Varela, Pilar
A1 de-Francisco, Ruth
A1 Monfort, David
A1 Molina-Arriero, Gema
A1 Hernandez-Camba, Alejandro
A1 Garcia-Alonso, Francisco Javier
A1 Van-Domselaar, Manuel
A1 Pajares-Villarroya, Ramon
A1 Nuñez, Alejandro
A1 Rodriguez-Moranta, Francisco
A1 Marin-Jimenez, Ignacio
A1 Robles-Alonso, Virginia
A1 Martin-Rodriguez, Maria Del Mar
A1 Camo-Monterde, Patricia
A1 Garcia-Tercero, Ivan
A1 Navarro-Llavat, Mercedes
A1 Arias-Garcia, Lara
A1 Hervias-Cruz, Daniel
A1 Kloss, Sebastian
A1 Passey, Alun
A1 Novella, Cynthia
A1 Vispo, Eugenia
A1 Barreiro-de Acosta, Manuel
A1 Gisbert, Javier P
K1 Crohn’s Disease
K1 Predictive factors
K1 Ustekinumab
K1 Área de Gestión Sanitaria Norte de Almería
K1 Área de Gestión Sanitaria Sur de Sevilla
AB Ustekinumab has shown efficacy in Crohn's Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the therapeutic paradigm of CD and generate hypotheses for future trials. The objective of this analysis was to determine whether baseline patient characteristics are predictive of remission and the drug durability of ustekinumab, and whether its positioning with respect to prior use of biologics has a significant effect after correcting for disease severity and phenotype at baseline using interpretable machine learning. Patients' data from SUSTAIN, a retrospective multicenter single-arm cohort study, were used. Disease phenotype, baseline laboratory data, and prior treatment characteristics were documented. Clinical remission was defined as the Harvey Bradshaw Index ≤ 4 and was tracked longitudinally. Drug durability was defined as the time until a patient discontinued treatment. A total of 439 participants from 60 centers were included and a total of 20 baseline covariates considered. Less exposure to previous biologics had a positive effect on remission, even after controlling for baseline disease severity using a non-linear, additive, multivariable model. Additionally, age, body mass index, and fecal calprotectin at baseline were found to be statistically significant as independent negative risk factors for both remission and drug survival, with further risk factors identified for remission.
PB MDPI
SN 2077-0383
YR 2022
FD 2022-08-03
LK http://hdl.handle.net/10668/21328
UL http://hdl.handle.net/10668/21328
LA en
NO Chaparro M, Baston-Rey I, Fernández Salgado E, González García J, Ramos L, Diz-Lois Palomares MT, et al. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on Ustekinumab. J Clin Med. 2022 Aug 3;11(15):4518
NO Cristina Rubin is supported by a grant from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III, Río Hortega CM21/00025) and co-funded by Fondo Europeo de Desarrollo Regional (FEDER).
DS RISalud
RD Apr 9, 2025